Omniose Announces Expanded Leadership Team to Develop Bioconjugate Vaccines Against Serious Bacterial Threats

BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today the expansion of the leadership team to include Timothy Cooke, Ph.D., MBA as Chief Executive Officer and Roman Fleck. Ph.D., MBA as Chairperson. Dr. Cooke has over 30 years of experience in the vaccine industry and is active in vaccine policy roles, including the Biotechnology Industry Representative to the US National Vaccine Advisory Committee